From Left Behind to Front and Center

By Janice Staber, MD There have been years when the hemostasis and thrombosis community might have felt a little left behind at the ASH annual meeting. However, here in Orlando, sessions on hemostasis and thrombosis were discussed front and center. From the...
The Roman God of Portals and More

The Roman God of Portals and More

By Binod Dhakal, MD, MS In 1951 a renowned hematologist from Harvard University, William Dameshek, MD, wrote an editorial in Blood providing seminal insight into myeloproliferative neoplasms (MPNs) — a group of disorders characterized by expansion of different myeloid...

Sunday’s Continuing Conversations With the Speakers

Continuing Conversations with the Speakers sessions allow for informal discussions with Scientific Program session speakers that will give interested individuals, especially trainees and junior investigators, increased accessibility both to information on the topic...

Mission (Im)Possible

By Binod Dhakal, MD, MS The year 1982 heralds the discovery of the first mutated genes to be identified in cancer, RAS. The three RAS genes — KRAS, NRAS, and HRAS — still constitute the most frequently mutated oncogene family in human cancers. However, despite more...

Saturday’s Continuing Conversations With the Speakers

Continuing Conversations With the Speakers sessions allow for informal discussions with Scientific Program session speakers that will give interested individuals, especially trainees and junior investigators, increased accessibility both to information on the topic...

Lymphoma Roundup: Verdict on This Year’s Annual Meeting

By Basem M. William, MD Since Thomas Hodgkin’s initial characterization of lymphomas in 1832 and the first administration of mustard to a patient with lymphoma 100 years later amid the secrecy of a World War II gas program, much has changed. Multiple recurrent themes...

Update on Precision Medicine Initiatives

Applying the principles of precision medicine to hematologic diseases is a priority for ASH. Precision medicine encompasses all approaches that use patient- and disease-specific information to prevent, diagnose, and treat a disease. The increasingly widespread use of...

ASH Clinical Practice Guidelines Update

ASH has long recognized the need for comprehensive guidelines and in the past three years has broken ground on developing and/or updating guidelines on several disease types, including venous thromboembolism (VTE), immune thrombocytopenia (ITP), acute myeloid leukemia...

Update on ASH Immunotherapies Initiatives

The field of immunotherapy has generated novel immune-based strategies and improved the utility of existing treatment options for various hematologic diseases. As such, ASH has had an enduring interest in improving immunotherapies for all hematologic diseases. This is...